Starting in 2014, it was being tested by the biotech company AOBiome for its possible health benefits on skin.[6] AOBiome started a Phase II trial of an intranasal formulation of the bacteria for migraines.[7][8]
^Stein, LY; Arp, DJ; Berube, PM; Chain, PS; Hauser, L; Jetten, MS; Klotz, MG; Larimer, FW; Norton, JM; Op den Camp, HJ; Shin, M; Wei, X (December 2007). "Whole-genome analysis of the ammonia-oxidizing bacterium, Nitrosomonas eutropha C91: implications for niche adaptation". Environmental Microbiology. 9 (12): 2993–3007. doi:10.1111/j.1462-2920.2007.01409.x. hdl:2066/36701. PMID17991028.
^George M. Garrity: Bergey’s manual of systematic bacteriology. 2. Auflage. Springer, New York 2005, Vol. 2: The Proteobacteria Part C: The Alpha-, Beta-, Delta-, and Epsilonproteabacteria, ISBN0-387-24145-0